Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Evolent Health

DB:9EH
Snowflake Description

Reasonable growth potential and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
9EH
DB
$478M
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Evolent Health, Inc., through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The last earnings update was 28 days ago. More info.


Add to Portfolio Compare Print
  • Evolent Health has significant price volatility in the past 3 months.
9EH Share Price and Events
7 Day Returns
24.1%
DB:9EH
4.1%
DE Healthcare Services
7.3%
DE Market
1 Year Returns
-55.9%
DB:9EH
0.9%
DE Healthcare Services
-17.7%
DE Market
9EH Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Evolent Health (9EH) 24.1% -39% -36.7% -55.9% -77.3% -
DE Healthcare Services 4.1% -8.3% -18.1% 0.9% 24.9% 85.3%
DE Market 7.3% -17.9% -25.8% -17.7% -25.6% -29%
1 Year Return vs Industry and Market
  • 9EH underperformed the Healthcare Services industry which returned 0.9% over the past year.
  • 9EH underperformed the Market in Germany which returned -17.7% over the past year.
Price Volatility
9EH
Industry
5yr Volatility vs Market

Value

 Is Evolent Health undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Evolent Health to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Evolent Health.

DB:9EH Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 11 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.1%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:9EH
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Healthcare Services Unlevered Beta Simply Wall St/ S&P Global 0.97
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.973 (1 + (1- 21%) (77.18%))
1.379
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.38
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.379 * 5.44%)
7.11%

Discounted Cash Flow Calculation for DB:9EH using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Evolent Health is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:9EH DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.11%)
2020 0.67 Analyst x4 0.63
2021 14.35 Analyst x2 12.51
2022 31.19 Analyst x2 25.38
2023 46.61 Analyst x2 35.41
2024 72.70 Analyst x2 51.57
2025 93.05 Est @ 27.99% 61.62
2026 111.17 Est @ 19.48% 68.73
2027 126.20 Est @ 13.52% 72.84
2028 137.99 Est @ 9.34% 74.36
2029 146.86 Est @ 6.42% 73.88
Present value of next 10 years cash flows $476.00
DB:9EH DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $146.86 × (1 + -0.39%) ÷ (7.11% – -0.39%)
$1,950.02
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $1,950.02 ÷ (1 + 7.11%)10
$981.00
DB:9EH Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $476.00 + $981.00
$1,457.00
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,457.00 / 84.72
$17.2
DB:9EH Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:9EH represents 0.87589x of NYSE:EVH
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.87589x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 17.20 x 0.87589
€15.06
Value per share (EUR) From above. €15.06
Current discount Discount to share price of €4.94
= -1 x (€4.94 - €15.06) / €15.06
67.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Evolent Health is available for.
Intrinsic value
>50%
Share price is €4.94 vs Future cash flow value of €15.06
Current Discount Checks
For Evolent Health to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Evolent Health's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Evolent Health's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Evolent Health's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Evolent Health's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:9EH PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-3.67
NYSE:EVH Share Price ** NYSE (2020-03-30) in USD $5.64
Germany Healthcare Services Industry PE Ratio Median Figure of 6 Publicly-Listed Healthcare Services Companies 11.1x
Germany Market PE Ratio Median Figure of 400 Publicly-Listed Companies 16.36x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Evolent Health.

DB:9EH PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NYSE:EVH Share Price ÷ EPS (both in USD)

= 5.64 ÷ -3.67

-1.54x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Evolent Health is loss making, we can't compare its value to the DE Healthcare Services industry average.
  • Evolent Health is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Evolent Health's expected growth come at a high price?
Raw Data
DB:9EH PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.54x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 11 Analysts
92%per year
Europe Healthcare Services Industry PEG Ratio Median Figure of 14 Publicly-Listed Healthcare Services Companies 2.29x
Germany Market PEG Ratio Median Figure of 254 Publicly-Listed Companies 1.2x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Evolent Health, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Evolent Health's assets?
Raw Data
DB:9EH PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $10.90
NYSE:EVH Share Price * NYSE (2020-03-30) in USD $5.64
Germany Healthcare Services Industry PB Ratio Median Figure of 7 Publicly-Listed Healthcare Services Companies 2.88x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.43x
DB:9EH PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NYSE:EVH Share Price ÷ Book Value per Share (both in USD)

= 5.64 ÷ 10.90

0.52x

* Primary Listing of Evolent Health.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Evolent Health is good value based on assets compared to the DE Healthcare Services industry average.
X
Value checks
We assess Evolent Health's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. Evolent Health has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Evolent Health expected to perform in the next 1 to 3 years based on estimates from 11 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
92%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Evolent Health expected to grow at an attractive rate?
  • Evolent Health's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Evolent Health's earnings growth is expected to exceed the Germany market average.
  • Evolent Health's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:9EH Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:9EH Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 11 Analysts 92%
DB:9EH Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 11 Analysts 11.3%
Europe Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 28.6%
Europe Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 8.5%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.3%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:9EH Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 11 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:9EH Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 1,650 136 29 1
2023-12-31 1,453 109 11 1
2022-12-31 1,215 84 -6 3
2021-12-31 1,032 63 -60 9
2020-12-31 962 47 -83 11
2020-03-30
DB:9EH Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 846 -43 -302
2019-09-30 803 -81 -121
2019-06-30 733 -42 -107
2019-03-31 685 -22 -86
2018-12-31 627 -21 -53
2018-09-30 548 10 -49
2018-06-30 506 -8 -49
2018-03-31 468 -18 -56
2017-12-31 435 -28 -61
2017-09-30 409 -55 -65
2017-06-30 362 -51 -64
2017-03-31 311 -49 -55

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Evolent Health's earnings are expected to grow significantly at over 20% yearly.
  • Evolent Health's revenue is expected to grow by 11.3% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:9EH Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 11 Analyst Estimates (S&P Global) See Below

All data from Evolent Health Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:9EH Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 0.34 0.34 0.34 1.00
2023-12-31 0.13 0.13 0.13 1.00
2022-12-31 -0.07 -0.07 -0.07 1.00
2021-12-31 -0.70 -0.24 -1.06 7.00
2020-12-31 -0.98 -0.40 -1.21 7.00
2020-03-30
DB:9EH Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -3.67
2019-09-30 -1.49
2019-06-30 -1.35
2019-03-31 -1.10
2018-12-31 -0.68
2018-09-30 -0.64
2018-06-30 -0.66
2018-03-31 -0.80
2017-12-31 -0.94
2017-09-30 -1.11
2017-06-30 -1.22
2017-03-31 -1.15

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Evolent Health will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Evolent Health's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Evolent Health has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Evolent Health performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Evolent Health's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Evolent Health does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Evolent Health's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Evolent Health's 1-year growth to the DE Healthcare Services industry average as it is not currently profitable.
Earnings and Revenue History
Evolent Health's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Evolent Health Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:9EH Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 846.38 -301.97 239.65
2019-09-30 802.96 -120.56 242.90
2019-06-30 732.77 -107.47 244.96
2019-03-31 685.11 -85.77 241.33
2018-12-31 627.06 -52.66 231.02
2018-09-30 547.69 -49.13 219.89
2018-06-30 505.65 -49.29 206.45
2018-03-31 468.43 -56.28 198.84
2017-12-31 434.95 -60.67 195.17
2017-09-30 409.23 -64.91 191.31
2017-06-30 361.53 -63.53 179.88
2017-03-31 310.98 -55.01 162.74
2016-12-31 254.19 -159.74 147.74
2016-09-30 212.24 -146.45 130.57
2016-06-30 192.43 -147.23 122.41
2016-03-31 146.33 220.18 102.93
2015-12-31 96.88 330.31 70.99
2015-09-30 50.82 322.44 38.35
2015-06-30 10.41 329.22 12.52
2015-03-31 -37.01 -0.56
2014-12-31 -31.14
2014-09-30 12.68 -29.27 7.01
2013-12-31 25.67 2.42 15.60

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Evolent Health has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Evolent Health has efficiently used its assets last year compared to the DE Healthcare Services industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Evolent Health improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Evolent Health's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Evolent Health has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Evolent Health's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Evolent Health's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Evolent Health is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Evolent Health's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Evolent Health's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Evolent Health Company Filings, last reported 2 months ago.

DB:9EH Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 929.05 293.67 102.82
2019-09-30 1,124.35 228.00 100.55
2019-06-30 1,146.76 225.64 96.87
2019-03-31 1,150.13 223.32 172.86
2018-12-31 1,189.36 221.04 228.32
2018-09-30 1,048.57 122.08 221.84
2018-06-30 1,051.38 121.85 197.98
2018-03-31 1,054.91 121.62 200.32
2017-12-31 1,046.31 121.39 238.43
2017-09-30 1,055.78 121.16 287.14
2017-06-30 894.45 120.94 124.00
2017-03-31 896.74 120.71 137.98
2016-12-31 912.11 120.28 178.90
2016-09-30 759.86 0.00 159.47
2016-06-30 768.14 0.00 132.72
2016-03-31 775.66 0.00 131.39
2015-12-31 934.58 0.00 155.17
2015-09-30 936.05 0.00 210.18
2015-06-30 948.70 0.00 219.37
2015-03-31 845.45 0.00 204.69
2014-12-31 37.20 0.00
2014-09-30 43.76 0.00 54.72
2013-12-31 69.30 0.00 67.89
  • Evolent Health's level of debt (31.6%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Evolent Health's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Evolent Health has sufficient cash runway for 1.2 years based on current free cash flow.
  • Unable to confirm if Evolent Health has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Evolent Health's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Evolent Health has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Evolent Health's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Evolent Health dividends. Estimated to be 0% next year.
If you bought €2,000 of Evolent Health shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Evolent Health's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Evolent Health's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:9EH Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 11 Analyst Estimates (S&P Global) See Below
Europe Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 1.7%
Germany Market Average Dividend Yield Market Cap Weighted Average of 323 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 1%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:9EH Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.00 1.00
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-03-30

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Evolent Health has not reported any payouts.
  • Unable to verify if Evolent Health's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Evolent Health's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Evolent Health has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Evolent Health's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Evolent Health's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Evolent Health afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Evolent Health has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Evolent Health's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Frank Williams
COMPENSATION $3,311,000
AGE 52
TENURE AS CEO 8.6 years
CEO Bio

Mr. Frank J. Williams co-founded Evolent Health, Inc. in 2011 and serves as its Chief Executive Officer since August 2011. Mr. Williams is a Director at Business Talent Group, LLC and Peer Health Exchange. He served as the Chief Executive Officer of The Advisory Board Company from June 2001 to September 1, 2008 and its Executive Vice President from September 2000 to August 2008. From June 2000 to January 2001, Mr. Williams served as the President of eHospital NewCo Inc., focused on developing and delivering health care content to patients and providers via the internet. He served as Management Consultant at Bain & Company from June 1988 to June 1990. From May 1999 to May 2000, Mr. Williams served as the President of MedAmerica OnCall. Mr. Williams also served as Vice President of Vivra Inc. and as the General Manager and President of Vivra Orthopedics from 1995 to 1999. He is a Founding Advisory Board Member of Health Velocity Capital. He served as the Chairman of the Advisory Board Company from November 15, 2004 to September 1, 2008. He served as the Vice Chairman at The Advisory Board Company since April 2, 2013 and served as its Director from 2001 to 2015. He serves as the Chairman of Evolent Health, Inc. He serves as a Director of Evolent Health, Inc. since August 2011. He served as an Independent Director of Market Force Information Inc. since July 2006. He has been a Board Member at Privia Health LLC. He has been Director of Syapse, Inc since March 1, 2018. Mr. Williams holds a Bachelor of Arts degree in Political Economies of Industrial Societies from University of California, Berkeley and a master of business administration from Harvard Business School.

CEO Compensation
  • Frank's compensation has increased whilst company is loss making.
  • Frank's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Evolent Health management team in years:

4
Average Tenure
50
Average Age
  • The tenure for the Evolent Health management team is about average.
Management Team

Frank Williams

TITLE
Co-Founder
COMPENSATION
$3M
AGE
52
TENURE
8.6 yrs

Seth Blackley

TITLE
Co-Founder
COMPENSATION
$2M
AGE
40
TENURE
8.6 yrs

Tom Peterson

TITLE
Co-Founder & COO
COMPENSATION
$1M
AGE
49
TENURE
9.2 yrs

Jonathan Weinberg

TITLE
Chief Legal Officer
COMPENSATION
$636K
AGE
51
TENURE
4 yrs

Norm Payson

TITLE
COMPENSATION
$430K
AGE
70
TENURE
0.8 yrs

Nicky McGrane

TITLE
Executive Vice President of Corporate Performance
COMPENSATION
$1M
AGE
51
TENURE
0.7 yrs

John Johnson

TITLE
Chief Financial Officer
AGE
35
TENURE
0.7 yrs

Lydia Stone

TITLE
VP, Chief Accounting Officer & Corporate Controller
AGE
43
TENURE
4.5 yrs

Bob East

TITLE
Investor Contact

Jordan Flynn

TITLE
VP & Chief Compliance Officer
TENURE
3.6 yrs
Board of Directors Tenure

Average tenure and age of the Evolent Health board of directors in years:

4.3
Average Tenure
61
Average Age
  • The tenure for the Evolent Health board of directors is about average.
Board of Directors

Seth Blackley

TITLE
Co-Founder
COMPENSATION
$2M
AGE
40
TENURE
1.9 yrs

Diane Holder

TITLE
Director
COMPENSATION
$190K
AGE
69
TENURE
8.6 yrs

Frank Williams

TITLE
Co-Founder
COMPENSATION
$3M
AGE
52

Bruce Felt

TITLE
Presiding Director
COMPENSATION
$195K
AGE
61

Michael D’Amato

TITLE
Independent Director
COMPENSATION
$175K
AGE
65
TENURE
3.9 yrs

Mary Duffy

TITLE
Independent Director
COMPENSATION
$175K
AGE
59
TENURE
2.5 yrs

David Farner

TITLE
Director
COMPENSATION
$175K
AGE
55
TENURE
5.5 yrs

Ken Samet

TITLE
Independent Director
COMPENSATION
$175K
AGE
61
TENURE
4.5 yrs

Cheryl Scott

TITLE
Independent Director
COMPENSATION
$175K
AGE
69
TENURE
4.3 yrs

Peter Grua

TITLE
Director
AGE
65
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
05. Dec 19 Buy Seth Blackley Individual 04. Dec 19 04. Dec 19 14,749 €6.07 €89,513
05. Dec 19 Buy Frank Williams Individual 03. Dec 19 03. Dec 19 35,000 €5.87 €205,452
19. Aug 19 Buy Kenneth Samet Individual 15. Aug 19 15. Aug 19 7,200 €6.34 €45,650
13. Aug 19 Buy Michael D’Amato Individual 09. Aug 19 09. Aug 19 15,000 €6.27 €94,009
X
Management checks
We assess Evolent Health's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Evolent Health has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Evolent Health, Inc., through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates through two segments, Services and True Health. The Services segment provides value-based care services that include Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows and engages patients; population health performance that delivers patient-centric cost effective care; delivery network alignments; and integrated cost and revenue management solutions. This segment also offers specialty care management solutions that support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation, and specific market dynamics; and comprehensive health plan administrative services that helps providers assemble the complete infrastructure required to operate, manage, and capitalize on a variety of financial and administrative management services. The True Health segment operates a commercial health plan for small and large businesses in New Mexico. Evolent Health, Inc. was founded in 2011 and is headquartered in Arlington, Virginia.

Details
Name: Evolent Health, Inc.
9EH
Exchange: DB
Founded: 2011
$433,109,445
84,722,479
Website: http://www.evolenthealth.com
Address: Evolent Health, Inc.
800 North Glebe Road,
Suite 500,
Arlington,
Virginia, 22203,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NYSE EVH Class A Common Stock New York Stock Exchange US USD 05. Jun 2015
DB 9EH Class A Common Stock Deutsche Boerse AG DE EUR 05. Jun 2015
Number of employees
Current staff
Staff numbers
3,400
Evolent Health employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/30 23:20
End of day share price update: 2020/03/30 00:00
Last estimates confirmation: 2020/03/26
Last earnings filing: 2020/03/02
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.